Market Overview

J.P. Morgan Reiterates Neutral Rating on Bristol Myers Squibb Co.

Share:
Related BMY
Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls
Bristol-Myers Squibb Posts Upbeat Q2 Results, Lifts Profit Forecast
Bristol-Myers Had Strong Revenues And Looks To Be Getting Stronger (Seeking Alpha)

In a report published Monday, J.P. Morgan & Co. reiterated its Neutral rating on Bristol Myers Squibb Co. (NYSE: BMY).

J.P. Morgan noted, “Maintain Neutral rating. We continue to view pipeline progression as the key driver for BMY shares and see a number of important events in 2013 including the launch of Eliquis, longer-term data on the company's PD-1 program as well as CV outcomes data for Onglyza. That said, we believe current valuation adequately reflects this with the stock trading at 18x trough 2013E EPS and remain Neutral on BMY shares.”

Bristol Myers Squibb Co. closed on Friday at $31.90.

Latest Ratings for BMY

DateFirmActionFromTo
Jul 2015Leerink SwannMaintainsOutperform
Jul 2015JefferiesMaintainsHold
Jun 2015Piper JaffrayInitiates Coverage onUnderperform

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Reiteration Analyst Ratings

 

Related Articles (BMY)

Get Benzinga's Newsletters